• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Ruxolitinib (JAK1 JAK2 inhibitor): remarking results on intestinal inflammation

Aubry

Senior Member
Messages
189
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854652/#!po=31.3333

C respresents inflamed dentric cells of the gut before and after administration of Ruxolitinib (the purple grapes are inflamed cells). This is causing probably the abnormalities seen in the micro biome of all ME/CFS patients.Since the micro biome is more and more investigated this could be very interesting for ME/CFS as well. Prof. Meirleir will start trials in 2018 with Filgotinib (another JAK inhibitor) in his patient groups.


Skin and intestinal GvHD responds to ruxolitinib
nihms781991f2.jpg
 

Attachments

  • C.jpg
    C.jpg
    72.7 KB · Views: 5

tyson oberle

Senior Member
Messages
211
Location
tampa, florida
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854652/#!po=31.3333

C respresents inflamed dentric cells of the gut before and after administration of Ruxolitinib (the purple grapes are inflamed cells). This is causing probably the abnormalities seen in the micro biome of all ME/CFS patients.Since the micro biome is more and more investigated this could be very interesting for ME/CFS as well. Prof. Meirleir will start trials in 2018 with Filgotinib (another JAK inhibitor) in his patient groups.


Skin and intestinal GvHD responds to ruxolitinib
nihms781991f2.jpg
 

tyson oberle

Senior Member
Messages
211
Location
tampa, florida
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854652/#!po=31.3333

C respresents inflamed dentric cells of the gut before and after administration of Ruxolitinib (the purple grapes are inflamed cells). This is causing probably the abnormalities seen in the micro biome of all ME/CFS patients.Since the micro biome is more and more investigated this could be very interesting for ME/CFS as well. Prof. Meirleir will start trials in 2018 with Filgotinib (another JAK inhibitor) in his patient groups.


Skin and intestinal GvHD responds to ruxolitinib
nihms781991f2.jpg
So did Dr De Meirleir start trials yet with Filgotinib?
 

Daffodil

Senior Member
Messages
5,875
so i think the HIV-related cognitive impairment probably has similar cause to our cognitive impairment. i did a google search and found that they are looking at Ruxolitinib (JAK inhibitor) as a potential treatment for HIV-cognitive impairment. I contacted a scientist, who told me some animal results look promising.

I think this is very good news for us!